Introduction
============

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is diagnosed based on symptoms such as bowel habits change and abdominal discomfort without any organic cause. Multiple factors, including altered brain-gut interactions, visceral hypersensitivity, gut dysbiosis, increased intestinal permeability, and psychosocial factors contribute to the pathogenesis of IBS.[@b1-jnm-24-528] In general, managing symptoms for patients with IBS involves life style modification, diet control, behavioral therapy, and medication.[@b2-jnm-24-528] Complementary or alternative therapies can be considered for patients with IBS who have not responded fully to conventional therapies, although the efficacy of the treatment of IBS is still unclear in most cases.[@b3-jnm-24-528]

*Aloe vera* (AV) is an herbal medication used as a remedy for various diseases in traditional medicine. It has been shown to have hepato-protective, anti-inflammatory, and anti-ulcerative benefits.[@b4-jnm-24-528] In particular, AV is commonly used as a strong laxative and as a substance to improve gastrointestinal motility.[@b5-jnm-24-528] However, the efficacy of AV has not been fully demonstrated in the patients with IBS despite several randomized controlled trials (RCTs).[@b6-jnm-24-528]--[@b8-jnm-24-528] The aim of this meta-analysis was to evaluate the efficacy and safety of AV in patients with IBS compared to placebo.

Materials and Methods
=====================

Search Strategy and Study Selection
-----------------------------------

This review and meta-analysis was based on the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRIS-MA) report guidelines.[@b9-jnm-24-528] From 1st January 1960 to 30th December 2017, we conducted a search of the PubMed, EMBASE and Cochrane library databases for studies. The following search terms were used: ("irritable bowel syndrome" OR "IBS" OR "irritable colon") and ("aloe vera" OR "aloe"). Two independent reviewers (S.W.H. and J.C.)searched and selected the articles. The studies that met all of the following criteria were included: (1) patient: adult patients with IBS; (2) intervention: AV group; (3) comparison: placebo group; (4) outcome: change of IBS symptoms and/or safety related to AV; and (5) study design: a prospective comparative study. All eligible studies compared AV to placebo in patients with IBS. Non-comparative studies, case reports, review articles, duplicated studies, abstracts, and pre-clinical studies were excluded from the meta-analysis.

Data Extraction and Quality Assessment
--------------------------------------

For eligible studies, data were independently extracted by 2 independent reviewers (S.W.H. and J.C.), and disagreements between the researchers were resolved through consensus. The following data were extracted for each study: author's name; year of publication; regimen, formulation, and treatment period of AV; numbers of total patients and patients who responded; changes in IBS symptoms scored between before and after the treatment; and number of adverse events. The data were extracted based on the assessment point of time presented in the each study. If the data were incomplete or unclear, we contacted the author for further information. For assessment of the quality of the RCTs, we used the risk of bias tool developed by the Cochrane Group.[@b10-jnm-24-528]

Study Outcomes
--------------

Primary outcome was standardized mean difference (SMD) of the change in severity of IBS symptoms as measured by patient-rated scales. Secondary outcomes were the response rate of IBS symptoms and adverse events.

Statistical Methods
-------------------

This meta-analysis was based on the Cochrane handbook for systematic review.[@b11-jnm-24-528] Dichotomous outcomes were calculated with risk ratio (RR) and 95% confidence interval (CI). Continuous outcomes with different units of measurement were analyzed with SMD and 95% CI. Intention-to-treat analysis included the study outcomes occurring during RCTs, regardless of whether the patients were taking the treatment to which they had been randomized. Per-protocol analysis included all outcomes from the patients who successfully adhered to the protocol during the trials. Subgroup analysis was also performed to evaluate the effect of AV according to the treatment period (1 month vs over 3 months). Heterogeneity among the studies was estimated using Cochrane's *Q* test and *I*^2^ statistics. A random-effects model was applied using the Mantel-Haenszel and inverse-variance methods for binary and continuous outcomes, respectively. If substantial heterogeneity was identified, the possible clinical causes were assessed. Publication bias was estimated by analyzing the asymmetry of a funnel plot, which was not applicable if fewer than 10 studies were included. Statistical analyzes were performed using Review Manager (RevMan) version 5.3. A *P*-value \< 0.05 was considered to be statistically significant.

Results
=======

Results of Search
-----------------

A total of 94 articles were identified through a combination of search terms. [Figure 1](#f1-jnm-24-528){ref-type="fig"} shows the flowchart of the study selection strategy. After removing 12 duplicates, 78 studies were excluded in the screening process based on titles and abstracts. Finally, 3 prospective RCTs were included in the meta-analysis after excluding a single-arm study.[@b6-jnm-24-528]--[@b8-jnm-24-528] Because the numeric outcomes could not be extracted from 1 study included in this meta-analysis, we collected additional unpublished data from the corresponding author.[@b7-jnm-24-528]

Characteristics of Included Studies
-----------------------------------

This meta-analysis included 3 prospective RCTs from 151 study participants (76 in the AV group and 75 in the placebo group). Among them, 2 studies[@b6-jnm-24-528],[@b8-jnm-24-528] were conducted via a parallel design, and the other[@b7-jnm-24-528] was a cross-over study. The characteristics and major outcomes of the included studies are summarized in [Table](#t1-jnm-24-528){ref-type="table"}.

Quality Assessment
------------------

The risk of bias for each RCT is shown in [Figure 2](#f2-jnm-24-528){ref-type="fig"}. The method of randomization and allocation concealment was clearly described in these studies,[@b6-jnm-24-528],[@b8-jnm-24-528] but the other[@b7-jnm-24-528] was not. In addition, Hutchings et al[@b7-jnm-24-528] reported incomplete outcomes and showed a high drop-out rate. The relatively short washout period may have created a potential risk of carry-over effect in this study.

Mean Differences in Irritable Bowel Syndrome Symptoms Scores
------------------------------------------------------------

Data from the IBS symptom scores before and after treatments were retrieved on different scales from the included RCTs. As in the study by Hutching et al,[@b7-jnm-24-528] unreported data were included in this meta-analysis. Moreover, data associated with the second treatment period were excluded from this meta-analysis because of concerns about the carry-over effect. The study by Hutching et al[@b7-jnm-24-528] showed a high drop-out rate, which made the result of the analysis unreliable. For this reason, intention-to-treat analysis was not performed. Meta-analysis showed a significantly greater difference for AV compared to placebo in terms of improvement of IBS symptom score (SMD, 0.41; 95% CI, 0.07--0.75; *P* = 0.020) ([Fig. 3A](#f3-jnm-24-528){ref-type="fig"}). There was no significant heterogeneity of effect among these included studies (*P* = 0.900; *I*^2^ = 0%). Except for the study by Hutching et al,[@b7-jnm-24-528] AV also showed a significant improvement of IBS symptoms score compared to placebo (SMD, 0.39; 95% CI, 0.02--0.77; *P* = 0.040) ([Fig. 3B](#f3-jnm-24-528){ref-type="fig"}).

Subgroup analysis was conducted to identify the efficacy of AV according to the treatment period (1 month vs over 3 months). In a short-term treatment for 1 month, AV showed a significantly favorable effect on improvement of IBS symptom score (SMD, 0.39; 95% CI, 0.03--0.77; *P* = 0.040), but not in a long-term treatment over 3 months (SMD, 0.18; 95% CI, −0.39--0.76; *P* = 0.530) compared to placebo ([Fig. 3C](#f3-jnm-24-528){ref-type="fig"}).

Response Rates
--------------

Two of the 3 included RCTs reported response rates, both intention-to-treat and per-protocol analysis were applied. In this meta-analysis, there was a higher response rate in the AV group compared to the placebo group (per-protocol analysis; pooled RR, 1.60; 95% CI, 1.00--2.54; *P* = 0.050) ([Fig. 4A](#f4-jnm-24-528){ref-type="fig"}), (intention-to-treat analysis; pooped RR, 1.69; 95% CI, 1.05--2.73; *P* = 0.030) ([Fig. 4B](#f4-jnm-24-528){ref-type="fig"}). There was no heterogeneity among included studies (*P* = 0.960; *I*^2^ = 0%).

Adverse Events
--------------

No significant difference in number of adverse events between the AV and placebo groups was reported in the studies. The follow-up duration ranged from 1 to 5 months ([Table](#t1-jnm-24-528){ref-type="table"}).

Discussion
==========

In this meta-analysis of 3 prospective RCTs regarding the efficacy of AV for the treatment of IBS, AV showed a significant improvement in IBS symptom scores and response rates compared to placebo. There was no significant heterogeneity among these RCTs. All of the included studies showed a favorable tendency toward the AV group in spite of no statistical significance due to the small number of enrolled patients in each study. This meta-analysis is the first to demonstrate the therapeutic efficacy of AV for controlling symptoms in patients with IBS.

AV is a plant belonging to the family *Liliaceae* and is commonly used to treat and prevent various diseases in traditional medicine.[@b12-jnm-24-528] Barbaloin, one of the major components in AV, plays a critical role as a laxative.[@b13-jnm-24-528],[@b14-jnm-24-528] It is metabolized to aloe-emodine-9-anthrone (AE-anthrone) by intestinal bacteria.[@b15-jnm-24-528] AE-anthrone enhances intestinal motility and increases paracellular permeability by inhibiting Na^+^/ K^+^-adenosine triphosphatase at the colonic mucosa.[@b14-jnm-24-528] In addition, it affects the release of prostaglandin-like materials and stimulates mucus secretions in the colon.[@b16-jnm-24-528] As a result, AV can increase the amount of water in the intestinal lumen and has a laxative effect in humans.[@b14-jnm-24-528] Therefore, AV may be a potential therapeutic agent in patients with constipation-predominant IBS or functional constipation.

The number of mast cells in the colonic tissue in patients with IBS is significantly higher compared to healthy controls.[@b17-jnm-24-528] In addition, pro-inflammatory cytokine levels in peripheral blood increased in a subset of patients with IBS.[@b18-jnm-24-528] These findings suggest that a low-grade inflammatory response in the colonic mucosa results in increased intestinal permeability and symptoms in patients with IBS. Previous studies reported that AV has an anti-inflammatory action on various medical conditions, such as a skin wounds, peptic ulcers, and colitis.[@b19-jnm-24-528] AV administration healed a gastric ulcer by reducing leukocyte adherence in post-capillary venules and serum TNF-alpha level, and elevating serum interleukin-10 level in rats.[@b4-jnm-24-528] In a prospective RCT, administration of AV reduced the clinical and histological disease activity in patients with ulcerative colitis.[@b20-jnm-24-528] Thus, the anti-inflammatory action of AV may be a possible mechanism of action for the treatment of IBS.

In subgroup analysis according to the treatment period, AV treatment showed a favorable efficacy for the improvement of IBS symptom scores at 1 month, but not over 3 months, compared to placebo. The incremental SMD in the improvement of IBS symptom scores by AV against placebo was 0.39 and 0.18 at 1 and over 3 months, respectively. It suggests the possibility of AV tachyphylaxis in the treatment of IBS. However, the possible mechanism of the progressive decrease in therapeutic response to AV in patients with IBS remains unclear. In the study by Davis et al,[@b6-jnm-24-528] the dropout rate of placebo group at 3 months was higher compared to the AV group (33.3% vs 22.6%). The relatively high drop-out rate of placebo group may result from the lack of efficacy, and the selection bias may underestimate the long-term efficacy of AV in patients with IBS in the study. Thus, further prospective RCTs are needed to determine the therapeutic efficacy of AV on the long-term treatment of IBS.

In this meta-analysis, serious adverse events were not reported. However, the long-term safety or rare adverse events of AV could not be demonstrated in this meta-analysis from the 3 prospective RCTs of 151 study participants conducted within 5 months. AV was classified as a group 2B material by the International Agency for Research on Cancer, suggesting that AV is possibly carcinogenic to humans, because there is sufficient evidence in experimental animals for the carcinogenicity of whole leaf extract of AV.[@b21-jnm-24-528] In a 2-year study, oral administration of AV significantly increased the incidence of colorectal adenoma and carcinoma compared to placebo in male and female rats.[@b22-jnm-24-528] Moreover, Modi and Hussan[@b23-jnm-24-528] reported a case of melanosis coli after the long-term oral administration of AV. To date, there is insufficient evidence for the carcinogenicity and long-term safety of AV in humans, especially patients with IBS who require long-term or repeated treatments due to the chronic, relapsing nature of the disease. Thus, a long-term prospective RCT is needed to determine the long-term safety as well as efficacy of AV in patients with IBS.

There are several limitations in this study. First, only 3 prospective RCTs were included in the meta-analysis. In addition, the randomization and allocation concealment method could not be found in the study by Hutching et al,[@b7-jnm-24-528] suggesting that it had a high possibility of bias in the study design. Second, the therapeutic efficacy of AV in patients with IBS could not be evaluated according to the subtype of IBS because only the study by Davis et al[@b6-jnm-24-528] performed a subgroup analysis according the IBS subtypes among these studies included in the meta-analysis. In the study, AV showed an improvement of the symptom scores for patients with diarrhea-predominant or mixed type IBS, especially in terms of the sub-scores of pain and bowel habit satisfaction. Recently, probiotics originated from AV leaf such as *Lactobacillus brevis* strains selectively inhibited the growth of harmful enteropathogens in the gut.[@b12-jnm-24-528] In a placebo-controlled trial, the frequencies of watery feces and abdominal pain in patients with IBS were significantly reduced by *L. brevis* KB290.[@b24-jnm-24-528] These findings suggest that the efficacy of AV on diarrhea-predominant or mixed type IBS may be explained by the probiotic effects of AV. Further studies are needed to evaluate the therapeutic efficacy and potential action mechanism of AV in patients with IBS based on the subtype.

In conclusion, AV was effective for the treatment IBS compared to placebo in this meta-analysis of RCTs. The short-term use of AV may be safe in patients with IBS.
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###### 

Characteristics and Major Outcomes of the Included Studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author      Year   Design           Region   Arms                           No. of patients   Age (mean ± SD)   Regimen                      Diagnostic criteria   Assessment point of time   Adverse event   Outcomes                                                  Type of outcomes
  ----------- ------ ---------------- -------- ------------------------------ ----------------- ----------------- ---------------------------- --------------------- -------------------------- --------------- --------------------------------------------------------- ------------------
  Davis       2006   Parallel/RCT     UK       *Aloe vera*                    31                NR                50 mL × 4 times/day per os   Rome II               1 and 3 months             None            Response rate[a](#tfn1-jnm-24-528){ref-type="table-fn"}   Dic

                                               Placebo                        27                NR                                                                                                              Mean change in IBS score                                  Con

  Hutchings   2011   Cross-over/RCT   UK       *Aloe vera*/Placebo            *55*              46.0 ± 13.6       60 mL × 2 times/day per os   Rome II               *5* months                 NR              GSRS\                                                     Con\
                                                                                                                                                                                                                EQ5D                                                      Con

                                               Placebo/*Aloe vera*            *55*              47.0 ± 13.7                                                                                                     SF-12\                                                    Con\
                                                                                                                                                                                                                IBSQOL                                                    Con

  Størsrud    2015   Parallel/RCT     Sweden   *Aloe vera* extract (AVH200)   33                43.9 ± 13.3       1tab × 2 times/day per os    Rome III              4 weeks                    None            Response rate[b](#tfn2-jnm-24-528){ref-type="table-fn"}   Dic

                                               Placebo                        35                44.2 ± 14.5                                                                                                     IBS-SSS\                                                  Con\
                                                                                                                                                                                                                HAD                                                       Con
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Responder was defined as a subject with improvement of 50 and over in irritable bowel syndrome (IBS) score.

Responder was defined as a subject with a reduction of ≥ 50 points on the IBS symptom severity scoring system (IBS-SSS).

UK, United Kingdom; RCT, randomized controlled study; NR, not reported; Dic, dichotomous; Con, continuous; GSRS, Gastrointestinal symptoms rating scale; EQ5D, EuroQol questionnaire; SF-12, short form 12 quality of life questionnaire; IBSQOL, IBS quality of life questionnaire; HAD, Hospital Anxiety and Depression scale.
